Developer docs
API playgroundTry for free, no card

Search company profiles

e-therapeutics PLC

Full company profile

uuid00sp1fo

Namestring
e-therapeutics PLC
Company typeenum
Private
Founded yearstring
-
Descriptiontext

e-therapeutics PLC operates under the trade name Tangram Therapeutics and is a for-profit biotechnology company developing RNAi-based medicines. Its functional focus is nucleic-acid therapeutics — leveraging RNA interference as the mechanism of action — which positions it within a specialized subset of the broader gene-silencing drug class. The company is headquartered in the City of London, United Kingdom, suggesting a UK-based R&D and corporate footprint, though no office network, subsidiary structure, or international presence was disclosed in the source.

The company's distinguishing technical layer is computational drug discovery applied to RNAi target identification, sequence design, and likely optimization of oligonucleotide chemistry and delivery characteristics. This implies an in silico platform — encompassing genomics data processing, target prioritization, and possibly proprietary modeling — that sits upstream of wet-lab validation. The source material does not specify named pipeline candidates, target indications, development stages, partnership vehicles, or platform architecture in detail, and the firm's public website at etherapeutics.co.uk resolved only to a loader page with no substantive product information. As a result, the precise scope of the pipeline, modality-specific chemistry capabilities, and any delivery-platform IP cannot be characterized from the available data.

No revenue mechanics, pricing model, customer agreements, licensing arrangements, or capital-raise history were disclosed in the source. The IPO status field in the firmographic data records the company as "private," though the use of "PLC" in the legal name traditionally denotes a UK public limited company structure; this inconsistency in the source data is noted but not resolved. No management team, board composition, headcount, funding rounds, or strategic transactions were disclosed. The company therefore should be treated as an opaque, early-profile biotech with disclosed positioning but limited verifiable operational detail.

Short descriptiontext

e-therapeutics PLC, operating as Tangram Therapeutics, is a UK-based biotech developing RNAi-based medicines using computational drug discovery to identify and advance nucleic-acid therapeutic candidates.

Ownership categoryenum
akta.pro rankint
HeadquartersCity Of London, United Kingdom
HQ citystring
City Of London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
RNAi therapeutics, computational drug discovery, biotech medicines, in silico drug discovery, RNA interference therapeutics
Industry1 code
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNAi Therapeutics
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

e-therapeutics plc operates as Tangram Therapeutics, a biotech company that develops RNAi-based medicines using computational drug discovery. The company combines RNA interference biology with in silico discovery methods to identify and advance therapeutic candidates for downstream development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No substantive product information available from the source. The source content shows only a loading/verification page with no details about the company's offerings, products, or services.

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The leading RNAi therapeutics company with multiple approved siRNA-based medicines. Directly comparable as it operates in the same RNAi drug discovery and development space serving similar patient populations and partners.

TypeBroad incumbent
Description

Now operating within Novo Nordisk's R&D organization, Dicerna's RNAi platform serves cardiometabolic and rare disease pipelines. Comparable as a large-incumbent channel that absorbs smaller RNAi platforms via acquisition.

TypeEmerging player
Description

Clinical-stage biotech developing tissue-targeted siRNA and other oligonucleotide therapeutics using Centyrin-based delivery. Emerging peer with overlapping RNAi approach but differentiated delivery technology.

TypeDirect peer
Description

Acquired by Novo Nordisk, Dicerna developed GalXC RNAi platform for liver and extrahepatic targets. Highly comparable RNAi platform company that demonstrates the partnership/M&A pathway for smaller RNAi platform players.

TypeDirect peer
Description

Clinical-stage RNA medicines company using stereopure oligonucleotide chemistry across RNAi and antisense modalities. Directly comparable as a platform-driven RNA therapeutics developer with overlapping delivery and target-selection challenges.

TypeBroad incumbent
Description

Large mRNA therapeutics company with broad pipeline across vaccines, oncology, and rare diseases. Comparable as a broader RNA-medicine incumbent using computational biology for RNA design and target selection.

TypeDirect peer
Description

UK-listed RNAi therapeutics company developing siRNA-based medicines, often via partnerships with larger pharma. Directly comparable as a London-based peer pursuing the same RNAi modality with a similar scale profile.

TypeBroad incumbent
Description

Lipid nanoparticle (LNP) delivery technology company enabling RNA-based therapeutics including siRNA. Comparable as a delivery-focused enabler in the broader RNAi/RNA therapeutics ecosystem.

TypeDirect peer
Description

Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs and a deep pipeline. Closely related peer operating in adjacent RNA-targeted modalities targeting similar indications.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company with a broad pipeline across multiple disease areas using proprietary delivery platforms. Directly comparable in modality (siRNA), target disease areas, and platform-driven discovery approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

e-therapeutics PLC

RNAi Therapeuticsetherapeutics.co.uk

e-therapeutics PLC, operating as Tangram Therapeutics, is a UK-based biotech developing RNAi-based medicines using computational drug discovery to identify and advance nucleic-acid therapeutic candidates.

What e-therapeutics PLC does

e-therapeutics PLC operates under the trade name Tangram Therapeutics and is a for-profit biotechnology company developing RNAi-based medicines. Its functional focus is nucleic-acid therapeutics — leveraging RNA interference as the mechanism of action — which positions it within a specialized subset of the broader gene-silencing drug class. The company is headquartered in the City of London, United Kingdom, suggesting a UK-based R&D and corporate footprint, though no office network, subsidiary structure, or international presence was disclosed in the source.

The company's distinguishing technical layer is computational drug discovery applied to RNAi target identification, sequence design, and likely optimization of oligonucleotide chemistry and delivery characteristics. This implies an in silico platform — encompassing genomics data processing, target prioritization, and possibly proprietary modeling — that sits upstream of wet-lab validation. The source material does not specify named pipeline candidates, target indications, development stages, partnership vehicles, or platform architecture in detail, and the firm's public website at etherapeutics.co.uk resolved only to a loader page with no substantive product information. As a result, the precise scope of the pipeline, modality-specific chemistry capabilities, and any delivery-platform IP cannot be characterized from the available data.

No revenue mechanics, pricing model, customer agreements, licensing arrangements, or capital-raise history were disclosed in the source. The IPO status field in the firmographic data records the company as "private," though the use of "PLC" in the legal name traditionally denotes a UK public limited company structure; this inconsistency in the source data is noted but not resolved. No management team, board composition, headcount, funding rounds, or strategic transactions were disclosed. The company therefore should be treated as an opaque, early-profile biotech with disclosed positioning but limited verifiable operational detail.

e-therapeutics PLC firmographics

Firmographics
Name
e-therapeutics PLC
Website
https://etherapeutics.co.uk
Company type
Private
Short description
e-therapeutics PLC, operating as Tangram Therapeutics, is a UK-based biotech developing RNAi-based medicines using computational drug discovery to identify and advance nucleic-acid therapeutic candidates.
Ownership category
akta.pro rank

e-therapeutics PLC industry classification

Industry
Product category
RNAi Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • Computational drug discovery
  • Biotech medicines
  • In silico drug discovery
  • RNA interference therapeutics

Where e-therapeutics PLC is headquartered

Location

Headquarters

HQ city
City Of London
HQ country
United Kingdom
HQ region
Europe

Markets served

e-therapeutics PLC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

e-therapeutics PLC product offering

Product offering

Core offering

e-therapeutics plc operates as Tangram Therapeutics, a biotech company that develops RNAi-based medicines using computational drug discovery. The company combines RNA interference biology with in silico discovery methods to identify and advance therapeutic candidates for downstream development.

Product overview

No substantive product information available from the source. The source content shows only a loading/verification page with no details about the company's offerings, products, or services.

Differentiator

Problem solved

Functional benefit

Companies that use e-therapeutics PLC

Customer profile

Ideal customer profiles1 record

e-therapeutics PLC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

e-therapeutics PLC partnerships and signals

Strategic signal

Expansion highlights2 records

e-therapeutics PLC competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: The leading RNAi therapeutics company with multiple approved siRNA-based medicines. Directly comparable as it operates in the same RNAi drug discovery and development space serving similar patient populations and partners.
  • Dicerna Pharmaceuticals: Acquired by Novo Nordisk, Dicerna developed GalXC RNAi platform for liver and extrahepatic targets. Highly comparable RNAi platform company that demonstrates the partnership/M&A pathway for smaller RNAi platform players.
  • Wave Life Sciences: Clinical-stage RNA medicines company using stereopure oligonucleotide chemistry across RNAi and antisense modalities. Directly comparable as a platform-driven RNA therapeutics developer with overlapping delivery and target-selection challenges.
  • Silence Therapeutics: UK-listed RNAi therapeutics company developing siRNA-based medicines, often via partnerships with larger pharma. Directly comparable as a London-based peer pursuing the same RNAi modality with a similar scale profile.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs and a deep pipeline. Closely related peer operating in adjacent RNA-targeted modalities targeting similar indications.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with a broad pipeline across multiple disease areas using proprietary delivery platforms. Directly comparable in modality (siRNA), target disease areas, and platform-driven discovery approach.

Broad incumbents

  • Dicerna Pharmaceuticals (Novo Nordisk subsidiary): Now operating within Novo Nordisk's R&D organization, Dicerna's RNAi platform serves cardiometabolic and rare disease pipelines. Comparable as a large-incumbent channel that absorbs smaller RNAi platforms via acquisition.
  • Moderna: Large mRNA therapeutics company with broad pipeline across vaccines, oncology, and rare diseases. Comparable as a broader RNA-medicine incumbent using computational biology for RNA design and target selection.
  • Genevant Sciences: Lipid nanoparticle (LNP) delivery technology company enabling RNA-based therapeutics including siRNA. Comparable as a delivery-focused enabler in the broader RNAi/RNA therapeutics ecosystem.

Emerging players

  • Aro Biotherapeutics: Clinical-stage biotech developing tissue-targeted siRNA and other oligonucleotide therapeutics using Centyrin-based delivery. Emerging peer with overlapping RNAi approach but differentiated delivery technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

e-therapeutics PLC social profiles

Digital presence

e-therapeutics PLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

e-therapeutics PLC leadership team

Management profile

Number of profiles

e-therapeutics PLC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

e-therapeutics PLC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about e-therapeutics PLC

What does e-therapeutics PLC do?

e-therapeutics plc operates as Tangram Therapeutics, a biotech company that develops RNAi-based medicines using computational drug discovery. The company combines RNA interference biology with in silico discovery methods to identify and advance therapeutic candidates for downstream development.

When was e-therapeutics PLC founded?

e-therapeutics PLC was founded in -1.

Where is e-therapeutics PLC based?

e-therapeutics PLC is headquartered in City Of London, United Kingdom, in the Europe region.

Who are e-therapeutics PLC's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Silence Therapeutics, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals. Broad incumbents are Dicerna Pharmaceuticals (Novo Nordisk subsidiary), Moderna and Genevant Sciences. Aro Biotherapeutics is listed as an emerging player.

Does e-therapeutics PLC have an API?

No public API is recorded for e-therapeutics PLC.

What industry is e-therapeutics PLC in?

e-therapeutics PLC's product category is RNAi Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswiree-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHe-therapeutics will present preclinical data on its MASH siRNA candidate ETX-312 at the EASL Congress in May 2025. In the GAN-DIO mouse model, ETX-312 reduced NAFLD Activity Score by up to 5 points and slowed fibrosis, with combination therapy achieving ≥2-point reductions. The company plans a regulatory submission by end of 2025.BusinessCloude-therapeutics eyes NASDAQ after raising £29me-therapeutics has completed a £28.9 million fundraise led by M&G Investment Management and Richard Griffiths, following its recent delisting from the London Stock Exchange's AIM market. The company intends to explore an Initial Public Offering (IPO) on NASDAQ in New York as part of its strategy to strengthen its balance sheet for drug discovery. CEO Ali Mortazavi cited significant risks within the UK investment market as a key driver for this strategic shift.BusinessCloude-therapeutics plc looks to US, slams risk appetite of UK investorse-therapeutics plc plans to delist from the London Stock Exchange's AIM market after raising £28.9m via a share subscription led by M&G Investment Management and Richard Griffiths. The subscription price of 15p is a 30% premium to the closing mid-market price of 11.55p on 8 April, with shareholder approval sought on 29 April 2024.BusinessCloudDrug discovery platform wins further institutional backinge-therapeutics raised £13.5 million in a share placing backed by M&G Investment Management. The Newcastle University spinout will use the funds to accelerate its RNAi drug pipeline and computational capabilities. CEO Ali Mortazavi said the investment supports its therapeutic programmes and datasets.YahooWhat Type Of Shareholders Make Up e-therapeutics plc's (LON:ETX) Share Registry?e-therapeutics plc has institutional investors, with Richard Griffiths as the largest shareholder holding 24% of shares. The second and third largest shareholders hold 9.8% and 9.6% respectively, and CEO Ahmad Mortazavi is among the top holders. No analyst coverage is available.PR NewswireOTC Markets Group Welcomes e-therapeutics plc to OTCQXe-therapeutics plc, a UK-based company specializing in computational drug discovery and RNA interference (RNAi) therapeutics, has qualified to trade on the OTCQX Best Market, beginning trading on September 24, 2021 under the symbol "ETXPF." The upgrade enables U.S. institutional and retail investors to buy and sell shares through online trading platforms and mobile apps, broadening the company's shareholder base. B. Riley Securities acted as the company's OTCQX sponsor.BusinessCloude-therapeutics raises £22.5m in share placinge-therapeutics raised £22.5 million in a conditional share placing. The Newcastle University spin-out expanded into RNA interference as a therapeutic modality last year. Ali Mortazavi, former CEO, oversaw a £11.6m growth funding raise to expand platform capabilities and relocate its head office to Oxford.Business LiveDrug firm e-therapeutics raises £22.5m after investors snap up sharesNewcastle-based drug firm e-therapeutics raised £22.5m by issuing 93.75m shares at 24p each on the London Stock Exchange. The company intends to use the capital to expand its proprietary drug discovery platform and advance RNAi therapeutic programmes through preclinical development. This funding follows previous raises in 2020 and comes as the company reports a 55% increase in operating losses.Vox Marketse-therapeutics raises £22.5m to expand drug discovery platform and asset pipelineUK-based e-therapeutics raised £22.5 million through an equity funding round to expand its computer-based drug discovery platform and asset pipeline. The company intends to use the net proceeds to advance RNAi therapeutic programmes into preclinical development, complete a First in Human clinical study, and enhance its computational capabilities. This capital injection follows a significant rise in the company's share value since the beginning of 2021.BusinessCloud‘Transformative’ figure replaced as e-therapeutics chair, remains as CEOe-therapeutics replaced CEO Ali Mortazavi as chair, appointing Trevor Jones as non-executive chairman. Jones, an independent director since 2015, will allow Mortazavi to focus on his CEO role. The company continues searching for an additional non-executive director.